Cohen-Armon M, Schreiber G, Sokolovsky M
J Cardiovasc Pharmacol. 1984 Nov-Dec;6(6):1148-55.
The possible interaction between the muscarinic receptor and the antiarrythmic drug amiodarone was studied physiologically in the guinea pig ileum, as well as by competition binding experiments in rat brain and cardiac tissues, using the highly specific tritiated muscarinic antagonist N-methyl-4-piperidyl benzilate. In these studies, amiodarone was found to affect both antagonist and agonist binding to the muscarinic receptor. The drug's inhibitory effect on the binding of antagonist to cerebral cortex muscarinic receptors was consistent with mutually exclusive binding of the compounds [KI = (1.0 +/- 0.2)10(-5) M]. On the other hand, in the brain stem and in cardiac tissues (atrium and ventricle) the inhibitory effect on the binding of muscarinic antagonist could not be fitted to a simple model of competitive inhibition. The possible mode of interaction is discussed. Compared with its activity in the cerebral cortex, amiodarone was a more potent inhibitor of muscarinic antagonist binding in the brain stem and in the atrium and ventricle of the heart [apparent KI values were (6.5 +/- 0.1)10(-6), (4.0 +/- 0.1)10(-6), and (4.0 +/- 0.1)10(-6) M, respectively]. In view of the KI values and the serum concentration of amiodarone observed therapeutically (10(-6) M), the effect of amiodarone on the muscarinic system may have clinical relevance. In both the brain stem and the cardiac preparations, amiodarone converted sites that bind agonist with high affinity into low-affinity sites. Agonist binding in the cerebral cortex was not affected.
在豚鼠回肠中通过生理学方法研究了毒蕈碱受体与抗心律失常药物胺碘酮之间可能的相互作用,同时在大鼠脑和心脏组织中利用高特异性的氚标记毒蕈碱拮抗剂N-甲基-4-哌啶基苯甲酸酯进行竞争结合实验。在这些研究中,发现胺碘酮会影响拮抗剂和激动剂与毒蕈碱受体的结合。该药物对拮抗剂与大脑皮层毒蕈碱受体结合的抑制作用与化合物的互斥结合一致[抑制常数(KI)=(1.0±0.2)×10⁻⁵ M]。另一方面,在脑干和心脏组织(心房和心室)中,对毒蕈碱拮抗剂结合的抑制作用不符合简单的竞争性抑制模型。讨论了可能的相互作用模式。与在大脑皮层中的活性相比,胺碘酮在脑干以及心脏的心房和心室中是更有效的毒蕈碱拮抗剂结合抑制剂[表观KI值分别为(6.5±0.1)×10⁻⁶、(4.0±0.1)×10⁻⁶和(4.0±0.1)×10⁻⁶ M]。鉴于治疗中观察到的胺碘酮的KI值和血清浓度(10⁻⁶ M),胺碘酮对毒蕈碱系统的作用可能具有临床相关性。在脑干和心脏制剂中,胺碘酮都将以高亲和力结合激动剂的位点转变为低亲和力位点。大脑皮层中的激动剂结合未受影响。